Why Shivering Occurs in Bronchopneumonia Patients
Shivering in bronchopneumonia patients is a physiological thermoregulatory response to fever, which occurs as part of the body's inflammatory reaction to pulmonary infection. This is a normal manifestation of the febrile response and represents one of the cardinal clinical features that helps identify pneumonia.
Pathophysiological Mechanism
Shivering occurs through a centrally-mediated pathway when infectious agents trigger fever. The process works as follows:
- Inflammatory mediators (particularly interleukin-17, interleukin-10, and other cytokines) are released in response to bacterial or viral infection in the lung parenchyma 1
- These pyrogenic substances act on the hypothalamic thermoregulatory center, raising the body's temperature set point
- The brain perceives the current body temperature as "too cold" relative to this new elevated set point
- Descending neural pathways through the dorsomedial hypothalamus and rostral raphe pallidus nucleus activate both somatic motor systems (causing shivering) and sympathetic responses (causing vasoconstriction and non-shivering thermogenesis) 2
- This coordinated response generates heat to reach the new elevated temperature target
Clinical Recognition
Shivering (also described as "shivers" or rigors) is specifically recognized as a suggestive clinical sign of pneumonia in current guidelines 3. The constellation of symptoms includes:
- Sweating, fevers, or shivers
- Temperature ≥38°C
- Cough and dyspnea
- Pleural pain
- Tachypnea
- New localizing chest examination signs
The presence of fever with shivering, particularly when accompanied by respiratory symptoms and absent runny nose, significantly increases the likelihood of pneumonia rather than upper respiratory infection 3.
Severity Correlation
The degree and persistence of fever (and associated shivering) correlates with disease severity in bronchopneumonia 1. Children with severe bronchopneumonia demonstrate:
- Longer duration of fever
- Higher inflammatory marker levels (CRP, PCT, IL-17, IL-10)
- More prolonged symptom resolution time
This relationship holds true across age groups, making fever and shivering important clinical markers for assessing pneumonia severity.
Management Implications
Temperature Control
While shivering indicates active fever, aggressive antipyretic therapy to achieve temperatures much below 38°C is not recommended, as moderate fever may support antiviral immune responses 4. Acceptable fever management includes:
- Antipyretics when temperature causes significant discomfort
- Avoiding excessive temperature suppression
- Monitoring for complications rather than treating fever itself
Sedation Considerations
In critically ill patients requiring mechanical ventilation, shivering can be managed with opioids and sedation, particularly when active temperature control is being used 5. However, this applies primarily to ICU settings rather than typical bronchopneumonia cases.
Clinical Pitfalls
Do not dismiss shivering as merely a benign symptom - it signals significant systemic inflammatory response and should prompt:
- Chest radiography if not already obtained
- Assessment of severity using clinical criteria
- Consideration of empiric antibiotic therapy based on severity
- Evaluation for complications if fever persists beyond expected timeframes (>72 hours for pneumococcal pneumonia, longer for atypical pathogens) 6
Persistent or recurrent shivering despite appropriate antibiotic therapy warrants reassessment for resistant organisms, complications (empyema, lung abscess), alternative diagnoses, or extrapulmonary complications 7.